NATCO Pharma (NATCOPHARM) Q3 25/26 earnings summary

Executive summary

• Q3FY26 consolidated revenue was INR 705.4 crore (INR 7,054 million), up from INR 651.1 crore YoY, with net profit at INR 151.3 crore (INR 1,513 million).

• EBITDA for the quarter stood at INR 216.8 crore (INR 2,168 million), with a margin of 30.7%.

• Interim dividend of INR 1.5 per equity share declared for Q3FY26.

• Strategic acquisition of a 35.75% stake in Adcock Ingram Holdings, South Africa, completed; profit consolidation started.

• Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025.

Financial highlights

• Q3FY26 revenue grew to INR 705.4 crore (INR 7,054 million) from INR 651.1 crore (INR 6,511 million) YoY.

• EBITDA margin was 30.7% for Q3FY26.

• Net profit reached INR 151.3 crore (INR 1,513 million), up from INR 1,324 million YoY.

• Earnings per share for Q3FY26 stood at INR 8.46.

• PAT margin for Q3FY26 was 19.9%.

Outlook and guidance

• FY26 revenue expected to be INR 4,300 crore, with PAT guidance of INR 150 crore for Q4.

• Focus on expanding product pipeline in the US, with 30 Para IVs and over 20 FTFs, including 14 approved products.

• Domestic business targeted to grow over 20% in FY26, driven by semaglutide launch.

• Board granted in-principle approval to evaluate the demerger of the Agro Chemicals business.

• Guidance excludes significant Revlimid contribution.